ID: hypothesis-h-78c49508e9
Hypothesis

NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD

Genetic or pharmacologic NRF2 activation using CDDO-EA or sulforaphane upregulates ARE gene transcription (NQO1, HO-1, GCLM), restoring redox homeostasis impaired across major neurodegenerative diseases.
🧬 NFE2L2 (NRF2)🩺 neurodegeneration🎯 Composite 71%💱 $0.59▼16.0%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.74 (15%) Evidence 0.72 (15%) Novelty 0.55 (12%) Feasibility 0.78 (12%) Impact 0.70 (12%) Druggability 0.88 (10%) Safety 0.62 (8%) Competition 0.65 (6%) Data Avail. 0.82 (5%) Reproducible 0.68 (5%) KG Connect 0.50 (8%) 0.710 composite

🧪 Overview

Genetic or pharmacologic NRF2 activation using CDDO-EA or sulforaphane upregulates ARE gene transcription (NQO1, HO-1, GCLM), restoring redox homeostasis impaired across major neurodegenerative diseases. Prioritized as most practical near-term opportunity due to multiple clinical-stage compounds and favorable risk profile.

🧬 Mechanism

🔗 Mechanism from KG for NFE2L2 (NRF2)

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    NRF2["NRF2"] -->|regulates| ARE_gene_transcription["ARE gene transcription"]
    NFE2L2["NFE2L2"] -->|regulates| ARE_gene_transcription_1["ARE gene transcription"]
    NRF2_activation["NRF2 activation"] -->|protective against| neurodegenerative_disease["neurodegenerative diseases"]
    NRF2_nuclear_localization["NRF2 nuclear localization"] -->|biomarker for| Alzheimer_s_disease["Alzheimer's disease"]
    NQO1["NQO1"] -->|regulates| redox_homeostasis["redox homeostasis"]
    HO_1["HO-1"] -->|regulates| redox_homeostasis_2["redox homeostasis"]
    TREM2["TREM2"] -->|regulates| microglial_metabolic_repr["microglial metabolic reprogramming"]
    TREM2_deficiency["TREM2 deficiency"] -->|causes| impaired_amyloid_plaque_e["impaired amyloid plaque enclosure"]
    TREM2_agonism["TREM2 agonism"] -->|protective against| amyloid_associated_neurot["amyloid-associated neurotoxicity"]
    neuronal_activity["neuronal activity"] -->|regulates| tau_propagation["tau propagation"]
    CDK5["CDK5"] -->|regulates| tau_packaging_into_exosom["tau packaging into exosomes"]
    NLRP3_inflammasome_activa["NLRP3 inflammasome activation"] -->|causes| IL_1__release["IL-1β release"]
    style NRF2 fill:#ce93d8,stroke:#333,color:#000
    style ARE_gene_transcription fill:#81c784,stroke:#333,color:#000
    style NFE2L2 fill:#ce93d8,stroke:#333,color:#000
    style ARE_gene_transcription_1 fill:#4fc3f7,stroke:#333,color:#000
    style NRF2_activation fill:#4fc3f7,stroke:#333,color:#000
    style neurodegenerative_disease fill:#ef5350,stroke:#333,color:#000
    style NRF2_nuclear_localization fill:#4fc3f7,stroke:#333,color:#000
    style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000
    style NQO1 fill:#4fc3f7,stroke:#333,color:#000
    style redox_homeostasis fill:#4fc3f7,stroke:#333,color:#000
    style HO_1 fill:#4fc3f7,stroke:#333,color:#000
    style redox_homeostasis_2 fill:#4fc3f7,stroke:#333,color:#000
    style TREM2 fill:#4fc3f7,stroke:#333,color:#000
    style microglial_metabolic_repr fill:#4fc3f7,stroke:#333,color:#000
    style TREM2_deficiency fill:#4fc3f7,stroke:#333,color:#000
    style impaired_amyloid_plaque_e fill:#4fc3f7,stroke:#333,color:#000
    style TREM2_agonism fill:#4fc3f7,stroke:#333,color:#000
    style amyloid_associated_neurot fill:#4fc3f7,stroke:#333,color:#000
    style neuronal_activity fill:#4fc3f7,stroke:#333,color:#000
    style tau_propagation fill:#4fc3f7,stroke:#333,color:#000
    style CDK5 fill:#4fc3f7,stroke:#333,color:#000
    style tau_packaging_into_exosom fill:#4fc3f7,stroke:#333,color:#000
    style NLRP3_inflammasome_activa fill:#4fc3f7,stroke:#333,color:#000
    style IL_1__release fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix4 supports3 contradicts
Supports
NRF2 activation protects in MPTP mouse model of PD
Supports
CDDO-TFEA crosses BBB and extends ALS mouse survival
Supports
NRF2 target gene polymorphisms associated with AD risk
Supports
Post-mortem AD brain shows impaired NRF2 nuclear localization
Contradicts
NRF2 activation may be compensatory, not pathogenic - activating may not add benefit
Contradicts
Bardoxolone caused cardiac events in CKD trials
Contradicts
Sulforaphane showed mixed BBB penetration results
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — NFE2L2

No curated PDB or AlphaFold mapping for NFE2L2 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for NFE2L2 (NRF2) →

No DepMap CRISPR Chronos data found for NFE2L2 (NRF2).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Falling
7d Momentum
▼ 1.2%
Volatility
Low
0.0022
Events (7d)
3
Price History
▼16.0%

💾 Resource Usage

API Calls
1
Total Cost
$0.0000

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF sulforaphane (60 mg daily) is administered to early-stage PD patients (Hoehn-Yahr stage 1-2) for 12 weeks, THEN peripheral blood mononuclear cell NQO1 mRNA expression will increase by ≥50% from basMean NQO1 mRNA fold-change of ≥1.5 in sulforaphane arm vs. ≤1.1 in placebo arm at week 12— no observation —pending0.65
IF CDDO-EA (10 mg/kg/day) is administered to ALS patients for 24 weeks, THEN the monthly decline in ALSFRS-R total score will be reduced by ≥30% compared to placebo, reflecting slowed disease progressMean ALSFRS-R slope of ≤1.2 points/month in CDDO-EA arm vs. ≥1.7 points/month in placebo arm— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF sulforaphane (60 mg daily) is administered to early-stage PD patients (Hoehn-Yahr stage 1-2) for 12 weeks, THEN peripheral blood mononuclear cell NQO1 mRNA expression will increase by ≥50% from baseline compared to placebo, reflecting successful NRF2 pathway activation.
Predicted outcome: Mean NQO1 mRNA fold-change of ≥1.5 in sulforaphane arm vs. ≤1.1 in placebo arm at week 12
Falsification: No significant difference in NQO1, HO-1, or GCLM expression between active and placebo arms; or <30% increase in ARE-driven genes despite drug exposure
pendingconf 55%
IF CDDO-EA (10 mg/kg/day) is administered to ALS patients for 24 weeks, THEN the monthly decline in ALSFRS-R total score will be reduced by ≥30% compared to placebo, reflecting slowed disease progression from neuroprotection.
Predicted outcome: Mean ALSFRS-R slope of ≤1.2 points/month in CDDO-EA arm vs. ≥1.7 points/month in placebo arm
Falsification: ALSFRS-R decline rate identical to or faster than placebo; or no difference in survival endpoints at 24 weeks
Metadata
_origin{'url': None, 'type': 'internal', 'tracked_at': '2026-04-28T14:39:39.911086'}
descriptionGenetic or pharmacologic NRF2 activation using CDDO-EA or sulforaphane upregulates ARE gene transcription (NQO1, HO-1, GCLM), restoring redox homeostasis impaired across major neurodegenerative diseas
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
5%
Debates
0
Incoming
1
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.